Glycoprotein Optimization of Lentiviral Vector
As a world-leading service provider in lentiviral vector services, Creative Biolabs is passionate about offering valuable solutions to develop promising lentiviral vector-based services for our clients. Our goal is to promote novel gene therapies to clinical trials for a wide range of disease therapy. We are building a team of talented and motivated scientists and technicians to pursue our commitment and have won a good reputation among our worldwide customers for successfully accomplishing numerous challenging projects in this field.
Introduction of Pseudotyping
Viral vector has been considered as one of the most perfect infection systems in a number of host cells. Research has indicated that lentivirus can infect a range of cells in mammals, but some cells are relatively difficult to infect because of the envelope proteins. The envelope proteins play an important role in regulating the tropism and immunogenicity of lentiviral vectors. Meanwhile, they can specifically bind to the surface of nature host cells or receptors, inducing the change of the protein structure and the refolding of the viral coat.
In recent years, many scientists have focused on discovering novel therapeutic vectors which have a specific or large cell transfection range. As a consequence, a wide variety of lentiviral vectors have been generated using envelope proteins from different species or engineered proteins. For instance, lentiviral vectors can be pseudotyped with a series of glycoproteins, such as glycoprotein G from vesicular stomatitis virus (VSV-G). The results suggest that pseudotyping is a significant method for producing various lentiviral vectors by different types of envelope proteins. To date, pseudotyping has been widely used for studying cell receptors, virus intrusion, as well as unknown or highly pathogenic viruses.
Figure 1. Production of lentiviral or retroviral pseudotypes. (Carnell, 2015)
Service at Creative Biolabs
Currently, the lentiviral vector has shown its efficacy for treating several diseases in human. Recent studies have demonstrated that pseudotyping is an effective strategy for lentiviral vector to expand host tropism and to increase the stability in cells. Creative Biolabs offers a large selection of lentiviral vector-based services, ranging from lentiviral vector construction, lentiviral expression, lentiviral cloning, lentiviral packaging to glycoprotein optimization. Thus far, we have successfully pseudotyped an HIV-based lentiviral vector using the envelope proteins of measles virus (MV). The cytoplasmic tails of MV proteins, including the fusion protein, have been truncated and CD46 has been regarded as a receptor for identifying MV tropism. Furthermore, we also provide the envelope protein assessment services for pseudotyping of lentiviral vectors. For instance, more recent studies conducted by our labs have evaluated the ability of many lentiviral vectors to infect a variety of host cells. Additionally, we have classified our pseudotyping services into five groups basing on the cell types, including but not limited to:
- Pseudotyping of Lentiviral Vector for Targeting Neuronal Cell
- Pseudotyping of Lentiviral Vector for Targeting Astrocytic Tumor Cells
- Pseudotyping of Lentiviral Vector for Targeting CD81+ Cells
- Pseudotyping of Lentiviral Vector for Targeting Hepatocytes
- Pseudotyping of Lentiviral Vector for Targeting Lung cells and Myocytes
To help our clients develop a safe and effective lentiviral vector, Creative Biolabs is continuously exploring novel technologies to provide broadly applicable pseudotyping services targeting a wide range of cell types. Moreover, we are committed to exploring modifications to the lentiviral vector-based technology for better applications. If you are interested in our services, please feel free to contact us for closer communication to learn how we can be involved in your project. Separate services or integrated end-to-end solutions are all welcomed.
Reference
- Carnell, G.W.; et al. (2015). Pseudotype-based neutralization assays for influenza: a systematic analysis. Cancer Cell. 6: 16.